regional expansion Neuraxpharm has a direct presence in over 20 European countries plus select international markets and is expanding through partnerships and acquisitions. This presents opportunities to cross-sell CNS therapies and collaborate on launch strategies in existing and adjacent markets, leveraging their local footprint and distributor networks.

CNS portfolio With a focus on central nervous system disorders including psychiatric and neurological conditions, there are clear sales opportunities to address unmet patient needs using Neuraxpharm's growing pipeline and collaborations, particularly for epileptic seizure detection, Parkinson's disease management, and long-acting injectable psychiatry therapies.

digital health Recent launches like EPISERAS an ai-powered wearable for early seizure detection indicate a push into digital health solutions. There is potential to offer integrated care packages, remote monitoring services, and partnerships with payers or providers to expand value-based CNS care.

manufacturing footprint Neuraxpharm manufactures many products in Spain and collaborates with regional manufacturers. This creates opportunities to propose regional supply agreements, faster time-to-market for new products, and potential co-development or contract manufacturing arrangements to support international launches.

partnership momentum Active collaborations with Dizlin Pharmaceuticals, ZIM Laboratories and Pharmathen point to a willingness to co-develop and co-market. This opens avenues for joint development deals, licensing of medicines, and expanding the portfolio into new geographies and delivery formats.